Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial

ConclusionsIn older patients with insomnia, as in younger patients, the efficacy of daridorexant is maximal on night-time and daytime variables at the higher dose of 50 mg. Older patients particularly require this dose to improve daytime functioning. Older patients are not at an increased risk of adverse events or residual effects the next morning after night-time administration of daridorexant, even at 50 mg. The dose of daridorexant does not need to be decreased for older patients.Clinical Trial RegistrationClinicalTrials.gov (NCT03545191) [first posted: 4 June, 4 2018],https://clinicaltrials.gov/ct2/show/NCT03545191.
Source: Drugs and Aging - Category: Geriatrics Source Type: research